On November 28, 2021 Subtle Medical, a leading healthcare technology company, and Bayer, a leading life science company with extensive expertise from diagnosis to care, reported a collaboration to explore opportunities to utilize AI (artificial intelligence) to aid in image acquisition in radiology (Press release, Bayer, NOV 28, 2021, View Source [SID1234596168]). The companies will investigate the potential of Subtle Medical’s state-of-the-art AI algorithm, SubtleGAD, for use in contrast-enhanced MRI exams to enhance image quality and will explore potential new areas for contrast media use.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At Bayer, we are constantly striving to advance medical knowledge and provide the best possible therapeutic and diagnostic options for physicians and patients," said Prof. Dr. Olaf Weber, Head of Radiology Research and Development at Bayer. "We are pleased to collaborate with Subtle Medical to harness the power of AI, with the ultimate goal of providing physicians with the means for optimal diagnosis for their patients."

Subtle Medical’s AI technologies acquire and improve high quality images from both accelerated and low dose scans.

MRI exams enable physicians to obtain detailed images of the body and help them answer critical medical questions in the diagnosis and monitoring of disease. In light of an aging population, the need for medical imaging to facilitate diagnosis, treatment decisions and therapy planning has grown. Artificial intelligence is a promising tool to support radiologists in their task to provide accurate and timely diagnosis to their patients, in addition to offering opportunities to speed up imaging exam times and reduce dose. In particular, Subtle Medical’s suite of deep learning technologies aid in higher quality image acquisition from both accelerated and low dose scans. Both companies are looking forward to joining forces to drive innovation in medical imaging.

"We are proud to collaborate with Bayer to combine our expertise and drive innovative solutions in light of the ever increasing demands of medical imaging," said Dr Ajit Shankaranarayanan, Chief Product Officer at Subtle Medical. "At Subtle Medical, we are committed to continued innovation and the development of AI tools that create a meaningful impact for both radiologists and patients."

Subtle Medical’s clinically validated AI-powered software solutions increase the efficiency of image capture by improving the quality of accelerated and low dose imaging. Subtle’s solutions are compatible with all scanner brands, models and field strengths so institutions can see the benefit across their entire scanner fleet. Meet with Subtle Medical at RSNA 2021.

"Bayer is a key partner due to their clinical expertise and proven track record in medical imaging. Such collaborations across the industry will be crucial to unlock the power of AI, ultimately benefiting patients, improving imaging capabilities and patient diagnosis worldwide," said Josh Gurewitz, Chief Commercial Officer at Subtle Medical.